Context Therapeutics (NASDAQ:CNTX) Stock Rating Raised to “Hold” at Zacks Research

Context Therapeutics (NASDAQ:CNTX) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.

Several other equities research analysts have also issued reports on CNTX. Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Wall Street Zen lowered shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Weiss Ratings raised shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 15th. Finally, Lifesci Capital lowered Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.40.

Context Therapeutics Stock Up 15.6%

NASDAQ CNTX opened at $0.22 on Tuesday. Context Therapeutics has a 1-year low of $0.18 and a 1-year high of $3.62. The business’s 50-day simple moving average is $0.29 and its 200-day simple moving average is $1.39.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, equities research analysts predict that Context Therapeutics will post -0.47 EPS for the current year.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Octagon Capital Advisors LP purchased a new stake in shares of Context Therapeutics during the first quarter worth about $13,755,000. BlackRock Inc. purchased a new position in Context Therapeutics in the second quarter valued at about $3,417,000. Blue Owl Capital Holdings LP acquired a new position in shares of Context Therapeutics in the 2nd quarter valued at approximately $1,625,000. Seven Fleet Capital Management LP acquired a new position in shares of Context Therapeutics in the 1st quarter valued at approximately $500,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Context Therapeutics during the 2nd quarter valued at approximately $416,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.